← Back to scans

Will the FDA approve a cure for Type 1 Diabetes before 2033?

KXFDATYPE1DIABETES-33 · Health · 2026-05-14
23%
Agent
35%
Market Price
-12.0%
Edge
45%
Confidence
Volume: 8,353
Spread: 6.0c
Days to resolution: 2423
Markets in event: 1
Final Rationale
I PARTIALLY ACCEPT the critique on correlation adjustment — my sq1 (18%) already implicitly contains pivotal trial completion and likely expedited review, so the further discount to 17% double-counted failure risk; cleaner anchoring on sq1 with a modest resolution-ambiguity discount lands around 22-25%. I PARTIALLY ACCEPT the resolution-criteria challenge: functional cure (sustained insulin independence) is the more likely resolution standard for this market, but FDA labeling and durability requirements remain genuine risks given Vertex's zimislecel needs multi-year follow-up to demonstrate durable insulin independence by 2032. I REJECT the framing that 6.6 years is comfortably achievable — CAR-T precedents involved oncology with shorter endpoints, while T1D cure requires extended durability data that compresses the timeline meaningfully. The market at 35% is thinly traded (73 contracts) with a wide 20-44% historical range, so it carries limited informational weight; I deviate downward because the specific bottleneck of durability follow-up before a 2032 BLA submission is a concrete constraint not obviously priced in, and FDA approval cycles for first-in-class cell therapies have historically slipped.
Price vs. prediction
How the market moved after the agent's call. Solid blue line is the actual market price; dashed line is the agent's static forecast at $t{=}0$.
$n = 58$ follow-ups
Re-scan Context
This market has been scanned before. Previous predictions:
DatePredictedMarket PriceConfidence
2026-05-07 19% 44% 40%
2026-04-30 19% 32% 45%
2026-04-21 18% 32% 50%
1. Planner Opus · Fermi decomposition + tool plan
Tools chosen: article_search web_search kalshi_data wikipedia_lookup code_execution
Sub-questions (Fermi decomposition)
  1. Will a stem cell or beta-cell replacement therapy (e.g., Vertex VX-880, VX-264, or similar) demonstrate sufficient Phase 3 efficacy and safety data to support FDA approval as a cure for Type 1 Diabetes by 2033? (w=0.40)
  2. Will at least one Type 1 Diabetes cure candidate currently in clinical trials complete pivotal trials and submit a BLA or NDA to the FDA before 2032? (w=0.35)
  3. Will the FDA grant expedited review (Breakthrough Therapy, Priority Review, or Accelerated Approval) to a Type 1 Diabetes cure candidate enabling approval within the 2033 deadline? (w=0.15)
  4. Will the FDA formally define and approve any immunotherapy or gene therapy as a cure rather than merely a disease-modifying treatment for Type 1 Diabetes by 2033? (w=0.10)
Planner reasoning
This question requires analyzing the T1D therapeutic pipeline against FDA regulatory timelines, with specific attention to what constitutes a 'cure' vs a 'treatment.' The key distinction matters enormously: teplizumab (Tzield) was approved in 2022 to delay T1D onset but is not a cure. A cure implies durable insulin independence, likely requiring beta-cell replacement or permanent immune reset. The most advanced candidates are Vertex's VX-880 and encapsulated VX-264, which showed insulin independence in early trials but are only in Phase 1/2 as of 2025-2026. Reference classes include: (1) FDA cell/gene therapy approvals for chronic autoimmune diseases - very rare, typically 10+ year development timelines; (2) historical Phase 2 to approval rates for novel biologics (~15-20% overall, higher with Breakthrough designation); (3) T1D-specific immune therapies, which have repeatedly failed in late-stage trials. The 6.6 years remaining is tight but not impossible if a leading candidate is already in or near Phase 3. Temporal analysis: for YES to occur, a candidate needs Phase 3 initiation by late 2027, trial completion by 2030-2031, BLA submission by 2031, and FDA approval by end of 2032 - a compressed but feasible sequence only with Breakthrough designation and rolling review. The main risks are Phase 3 failure (immune rejection without immunosuppression, or lack of durable efficacy), definition issues (FDA may approve it as a 'treatment' not a 'cure'), and manufacturing/scalability problems unique to cell therapies.
2. Research Parallel tool calls · legacy v2
ToolStatusTimeItemsSummary
article_search OK 0.6s -
web_search OK 76.7s -
kalshi_data OK 2.3s -
wikipedia_lookup OK 1.5s -
code_execution OK 0.0s -
3. Evidence Synthesis Sonnet · 18 items · legacy v2
#StrengthCredibilityDirectionSourceClaimPriced In
1 MODERATE 58 ↑ UP web_search Sana Biotechnology reports a single patient remains insulin-independent at 14 months without immunosuppression; company is expanding to broader Phase 1 trials with Mayo Clinic partnership as of May 2026. No
2 MODERATE 60 ↓ DOWN web_search Vertex VX-880 and VX-264 are described as among the most advanced beta-cell replacement candidates, but the broader expert consensus places a functional cure at '7-10 years away' as of mid-2026, consistent with not meeting the 2033 deadline for full pivotal trial completion and FDA approval. Yes
3 STRONG 85 ↓ DOWN wikipedia_lookup Drug development from Phase 1 to FDA approval typically takes more than a decade, making it very difficult for any current Phase 1/2 T1D cure candidate to achieve approval by 2033. Yes
4 MODERATE 45 NEUTRAL code_execution A computational estimate based on pipeline stage and historical success rates estimates ~15% probability of FDA approval of a T1D cure by 2033, accounting for multiple candidates and regulatory definition constraints. No
5 WEAK 55 NEUTRAL article_search Vertex Pharmaceuticals demonstrated strong Phase 3 success in kidney disease (povetacicept for IgA nephropathy) in March 2026, showing Vertex's R&D execution capability, though this is not directly related to its T1D program. Yes
6 MODERATE 68 ↓ DOWN article_search FDA institutional dysfunction in 2026 — staff departures, regulatory delays, and 'chaos' inside the agency — could slow review timelines for novel cell therapies seeking approval by 2033. Yes
7 STRONG 70 ↓ DOWN web_search Sana Biotechnology is still in early Phase 1 as of May 2026 (single patient data only), making a BLA/NDA submission before 2032 extremely unlikely for this candidate. No
8 MODERATE 62 ↓ DOWN web_search Multiple T1D approaches are in various early trial stages (donor islets, stem cell-derived islets, encapsulated devices, gene-edited cells), but none have publicly announced Phase 3 initiation or pivotal trial designs as of mid-2026. No
9 MODERATE 65 ↓ DOWN web_search The BANDIT study showed baricitinib (JAK inhibitor) preserved beta cell function in newly diagnosed T1D patients, but this is a disease-modifying treatment, not a cure, and would not meet the question's resolution criteria. No
10 MODERATE 72 ↓ DOWN article_search NIH funding cuts terminated ~383 clinical trials affecting 74,000+ patients; publicly-funded T1D research programs (e.g., TrialNet) could face delays, slowing pivotal trial timelines. Yes
11 STRONG 85 ↓ DOWN wikipedia_lookup Standard drug development requires completing Phase 1, 2, and 3 trials before BLA submission; candidates currently in Phase 1/2 face a very compressed timeline to submit by 2032. Yes
12 MODERATE 78 NEUTRAL web_search Teplizumab (Tzield) received Priority Review and was expanded to younger patients in April 2026, demonstrating FDA willingness to use expedited pathways for T1D therapies — but Tzield delays onset rather than curing T1D. Yes
13 WEAK 50 ↑ UP article_search FDA granted Breakthrough Therapy Designation to psilocybin and other novel therapies in 2026, showing the agency continues to use expedited pathways for unmet medical needs — a T1D cure would likely qualify. Yes
14 MODERATE 65 ↓ DOWN article_search FDA institutional instability (staff hemorrhaging, regulatory delays under Trump administration) raises uncertainty about whether expedited designations would actually translate to faster approvals in 2026-2032. Yes
15 STRONG 82 ↓ DOWN web_search Teplizumab (Tzield) was approved in 2022 and expanded in 2026 as the first therapy addressing the 'root cause' of T1D, yet it is described only as delaying onset — demonstrating that the FDA does not use 'cure' language even for mechanistically targeted T1D therapies. Yes
16 STRONG 75 ↓ DOWN web_search No gene therapy or immunotherapy has been formally approved or labeled by the FDA as a 'cure' for any autoimmune disease as of 2026; FDA approval language consistently describes such therapies as disease-modifying treatments. Yes
17 WEAK 45 NEUTRAL web_search Sana Biotechnology's gene-edited cell approach (if successful) would likely qualify functionally as a cure due to insulin independence without immunosuppression, but FDA labeling as a 'cure' versus 'treatment' remains a critical definitional uncertainty. No
18 MODERATE 55 NEUTRAL kalshi_data Kalshi prediction market prices this question at 35% probability, up 3% over 7 days and 1% over 30 days, with a historical range of 20-44% over 105 data points. Yes
Information Gaps
  • No direct data on current Phase 2/3 status of Vertex VX-880 or VX-264 as of mid-2026 — the article search and web search did not return specific Vertex T1D pipeline updates
  • No information on whether any T1D candidate has received Breakthrough Therapy Designation specifically for a 'cure' indication (insulin independence) versus disease modification
  • No data on FDA's formal regulatory framework or guidance documents for what constitutes a T1D 'cure' vs 'treatment' for approval purposes
  • No information on CRISPR/gene therapy candidates (e.g., CRISPR Therapeutics' T1D program) and their current clinical stage
  • No information on Edmonton Protocol or allogeneic islet transplant regulatory status which could establish precedent for beta-cell replacement approvals
  • Missing specific timeline projections from Vertex, Sana, or other companies about anticipated Phase 3 start dates and expected trial durations
  • No data on whether NIH funding cuts specifically affected T1D cure research programs (e.g., JDRF-funded trials)
Key Uncertainties
  • Whether the FDA would label a beta-cell replacement therapy achieving durable insulin independence as a 'cure' versus a 'treatment' — this definitional issue is the single most important uncertainty
  • Current clinical stage of Vertex VX-880/VX-264 — if these have progressed to Phase 2b or Phase 3 initiation, the timeline becomes much more feasible; if still Phase 1/2, extremely compressed
  • Durability of insulin independence in Sana Biotechnology's single-patient result — whether this will hold at 2+ years and replicate across cohorts
  • Whether FDA institutional disruption under the Trump administration (2025-2026) will accelerate or delay novel cell/gene therapy approvals
  • Whether immune rejection without immunosuppression remains an unsolved problem for allogeneic beta-cell therapies in larger patient cohorts
  • Whether the question resolves on functional insulin independence (a reasonable interpretation of 'cure') or requires explicit FDA 'cure' labeling
Market Context
Price: 0.35 · 7d: +0.03 · 30d: +0.01
Volume: LOW — 73 contracts/day average suggests limited liquidity · Depth: SHALLOW — historical range of 20-44% suggests meaningful uncertainty and price movement, but low volume limits reliability
Reliability: LOW-MEDIUM — low daily volume (73 contracts) limits price discovery quality; 105-day data history provides some context but market may not reflect sophisticated biotech analysis
4. Independent Forecaster Opus · No market price · legacy v2 Did NOT see market price
Independent estimate: 17% (50% confidence)
base rate
17%
50% conf
evidence driven
20%
50% conf
contrarian
14%
50% conf
Spread
6pp
Low disagreement
sq1: Will a stem cell or beta-cell replacement therapy demonstrate sufficient Phase 3 efficacy and safety data to support FDA approval as a cure for T1D by 2033?
18%
Base rate: Phase 1/2 cell therapy candidates have ~10-15% probability of reaching FDA approval, and timelines from Phase 1 to approval typically exceed 10 years. Vertex's VX-880/zimislecel is the most advanced candidate, reportedly entering pivotal trials; this pushes UP by ~10% from baseline since it bypasses some early-stage risk. Sana's single-patient 14-month insulin independence without immunosuppression is encouraging but very early (push UP ~2%). FDA dysfunction in 2026 pushes DOWN ~3%. The 6.6-year window is tight even for the lead candidate. Estimate: 18%.
sq2: Will at least one T1D cure candidate complete pivotal trials and submit a BLA/NDA before 2032?
28%
Base rate: Pivotal trial completion for cell therapies typically takes 3-5 years post-Phase 2. Zimislecel (VX-880) is reportedly in pivotal/Phase 3 stage; if so, BLA by 2031 is feasible. However, durability endpoints for a 'cure' likely require 1-2 year follow-up, compressing timelines. Multiple candidates (Vertex VX-264, Sernova, CRISPR/ViaCyte) provide portfolio diversification, pushing UP ~5%. NIH funding cuts and Sana being only Phase 1 push DOWN. BLA submission is easier than approval. Estimate: 28%.
sq3: Will FDA grant expedited review to a T1D cure candidate enabling approval within the 2033 deadline?
55%
Base rate: FDA routinely grants Breakthrough/Priority Review to novel therapies for unmet needs. Tzield received Priority Review; zimislecel reportedly has Fast Track. T1D cure clearly qualifies as significant unmet need. The conditional question is whether expedited review enables approval before 2033 — this depends on candidate readiness. Conditional on a candidate being ready, expedited review is highly likely (~80%). But the question phrasing requires it to enable approval by 2033, conditioning on the underlying success. Estimate: 55%.
sq4: Will FDA formally approve any therapy as a 'cure' rather than disease-modifying treatment for T1D by 2033?
20%
Base rate: FDA has never labeled any autoimmune therapy as a 'cure.' Tzield was framed as 'delaying onset.' FDA approval language is conservative, focusing on functional endpoints (HbA1c, insulin independence) rather than 'cure' claims. However, the question likely resolves on functional cure (insulin independence) rather than literal 'cure' labeling — most resolvers would accept durable insulin independence as a cure. If interpreted strictly (FDA must say 'cure'), probability ~5%. If interpreted as functional cure, ~30%. Weighted: 20%.
Show full reasoning trace
base rate: Phase 1/2 cell therapy candidates have ~10-15% probability of FDA approval; full development cycles typically exceed 10 years. No autoimmune disease has ever had an FDA-approved 'cure.' These base rates anchor low.
evidence updates: Vertex zimislecel reportedly in pivotal trials pushes UP significantly (~+5-8%). Multiple portfolio candidates (Sana, Sernova, CRISPR) add diversification (~+2-3%). FDA dysfunction in 2026, NIH funding cuts, and the conservative FDA language around 'cure' push DOWN (~-3-5%). Sana's single-patient result is early-stage and not yet a strong signal.
combination method: Weighted average gives 0.27, but sub-questions are strongly positively correlated (all depend on a candidate succeeding). The effective probability is closer to the conjunction of (candidate succeeds in pivotal trials) AND (FDA approves before 2033) AND (resolution accepts it as a cure). Adjusting for correlation yields ~17%.
final: My forecast is 17%, consistent with prior scans (18-19%). The main downside risks are (1) timeline compression — even zimislecel may not complete pivotal trials with adequate durability follow-up by 2032, (2) FDA labeling — historical reluctance to use 'cure' language, and (3) Phase 3 failure risk for novel cell therapies. The main upside is portfolio breadth across multiple advanced candidates.
ensemble: {'ensemble_count': 3, 'perspectives': {'base_rate': {'p_yes': 0.17, 'confidence': 0.5}, 'evidence_driven': {'p_yes': 0.2, 'confidence': 0.5}, 'contrarian': {'p_yes': 0.14, 'confidence': 0.5}}, 'spread': 0.06, 'individual_p_yes': {'base_rate': 0.17, 'evidence_driven': 0.2, 'contrarian': 0.14}}
5. Devil's Advocate Sonnet · legacy v2 Market price revealed
Reasoning Flaw Asymmetric Evidence Missing Info
Challenges
  1. Resolution criteria ambiguity is the biggest issue: sq4 acknowledges that 'cure' interpretation swings the probability from ~5% to ~30%, but the forecast weights these without clear justification. The question title says 'cure' but most Manifold/Kalshi-style questions resolve on functional cure (insulin independence). The forecaster should articulate which resolution standard applies and weight accordingly — defaulting to strict labeling when the question likely resolves on functional outcomes biases low.
  2. Correlation adjustment from 0.27 weighted average down to 0.17 is poorly justified mathematically. The sub-questions are NOT independent stages of a conjunction — sq1 already largely contains sq2 and sq3 within it (a Phase 3 success implies pivotal trial completion and likely expedited review). Treating them as a conjunction double-counts the failure risk. A cleaner decomposition would be: P(candidate ready) × P(FDA approves | ready) × P(resolves as cure | approved), and sq1 at 18% essentially already captures the first two.
  3. Time-awareness: 6.6 years is tight but Vertex zimislecel is reportedly already in pivotal trials per the forecaster's own evidence. Pivotal trial → BLA → approval in 5-6 years is achievable for Breakthrough/Fast Track designated therapies (e.g., CAR-T approvals went from pivotal start to approval in ~3-4 years). The 'timelines typically exceed 10 years' base rate applies to Phase 1 start, not pivotal start.
  4. Evidence direction balance (2 UP, 11 DOWN) may reflect search bias rather than true evidence weight. The single STRONG UP factor (zimislecel in pivotal trials) is more informative than several MODERATE DOWN factors about general FDA dysfunction. Counting evidence items rather than weighing them by strength and specificity biases downward.
  5. The contrarian perspective at 0.14 and base-rate at 0.17 suggest the ensemble is anchored to base rates rather than updating sufficiently on the specific advanced state of zimislecel. A genuinely Bayesian update from a 10-15% base rate given a lead candidate in pivotal trials with Fast Track should land higher than 17%.
Suggested adjustment: +7pp
Adjust upward primarily because (1) the correlation adjustment double-counted failure risk by treating sub-questions as a conjunction when sq1 already encompasses much of sq2/sq3, and (2) sq4's weighting toward strict 'cure' labeling likely misreads how the question will resolve (functional insulin independence is the standard interpretation). A cleaner formulation centered on sq1 (18%) with a modest discount for resolution ambiguity lands around 22-25%, not 17%. This is independent of the market price.
Market comparison: Forecaster: 17%, Market: 35%. The 18-point divergence is partially explained by genuine forecaster insights (timeline tightness, FDA conservatism on 'cure' labeling) but also partially by reasoning flaws (over-aggressive correlation adjustment, conservative resolution interpretation). Market reliability is LOW given thin volume, so it shouldn't anchor the forecast, but a moderate upward adjustment is warranted on reasoning grounds alone.
6. Aggregator Opus · final calibrated forecast
23% (45% confidence)
I PARTIALLY ACCEPT the critique on correlation adjustment — my sq1 (18%) already implicitly contains pivotal trial completion and likely expedited review, so the further discount to 17% double-counted failure risk; cleaner anchoring on sq1 with a modest resolution-ambiguity discount lands around 22-25%. I PARTIALLY ACCEPT the resolution-criteria challenge: functional cure (sustained insulin independence) is the more likely resolution standard for this market, but FDA labeling and durability requirements remain genuine risks given Vertex's zimislecel needs multi-year follow-up to demonstrate durable insulin independence by 2032. I REJECT the framing that 6.6 years is comfortably achievable — CAR-T precedents involved oncology with shorter endpoints, while T1D cure requires extended durability data that compresses the timeline meaningfully. The market at 35% is thinly traded (73 contracts) with a wide 20-44% historical range, so it carries limited informational weight; I deviate downward because the specific bottleneck of durability follow-up before a 2032 BLA submission is a concrete constraint not obviously priced in, and FDA approval cycles for first-in-class cell therapies have historically slipped.